Biotechnology - Licensing, Inflammatory diseases

Filter

Popular Filters

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Novartis enters into a collaboration for Il-17 inhibitor

06-08-2013

US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Array BioPharma signs up to $387 million deal

30-07-2013

In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen

07-01-2013

Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb

05-10-2012

USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi

30-09-2012

As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

BioLineRx inks deal with Compugen

14-12-2011

Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top